SBWire

Recently published research from Global Markets Direct, "Growth Hormone Deficiency - Pipeline Review, H1 2014", is now available at Fast Market Research

Recently published research from Global Markets Direct, "Curaxys, S.L. - Product Pipeline Review - 2014", is now available at Fast Market Research

New Pharmaceuticals market report from Global Markets Direct: "Acute Ischemic Stroke - Pipeline Review, H1 2014"

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Recently published research from Global Markets Direct, "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2014", is now available at Fast Market Research

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

GlobalData's clinical trial report, "Ureter Cancer Global Clinical Trials Review, H1, 2014" provides data on the Ureter Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ureter Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ureter Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H1 2014', provides an overview of the Alcohol Addiction's therapeutic pipeline.

Fast Market Research recommends "Fujifilm Corporation - Product Pipeline Review - 2014" from Global Markets Direct, now available

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Arrhythmias - Pipeline Review, H1 2014

Fast Market Research recommends "Pulmonary Tuberculosis - Pipeline Review, H1 2014" from Global Markets Direct, now available

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Curis, Inc. - Product Pipeline Review - 2014

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

New Pharmaceuticals market report from Global Markets Direct: "Cancer Pain - Pipeline Review, H1 2014"

New Pharmaceuticals market report from Global Markets Direct: "Myelofibrosis - Pipeline Review, H1 2014"

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Fast Market Research recommends "Hyperlipidemia - Pipeline Review, H1 2014" from Global Markets Direct, now available

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

H1N1 Infection - Pipeline Review, H1 2014

Catalyst Pharmaceutical Partners, Inc. - Product Pipeline Review - 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.